title: Evaluation of platelet activation, coagulation, and fibrinolytic activation in patients with symptomatic lacunar stroke.
abstract: BACKGROUND
  It is unclear whether hemostasis plays a role in the pathogenesis of ischemic stroke subtypes.
  
  
  OBJECTIVE
  We aimed to investigate the possible relationship between different hemostatic markers and lacunar stroke.
  
  
  RESULTS
  The study consisted of 30 patients with symptomatic lacunar stroke and 30 healthy age-matched healthy individuals. We analyzed the values of "Mean Platelet Volume," D-dimer, "soluble p-selectin," "Plasminogen Activator Inhibitor Type-1" (PAI-1), "Thrombin-Activatable Fibrinolysis Inhibitor" (TAFI), and "Platelet Factor 4" (PF4) in patients with lacunar infarct and compared these values to those of control individuals. There were significant differences for D-dimer, mean platelet volume, thrombin-activatable fibrinolysis inhibitor, and platelet factor 4 values in symptomatic lacunar stroke group compared with the control group (P < 0.01).
  
  
  CONCLUSIONS
  Different hemostatic factors may play a role in the pathogenesis of lacunar stroke. Evaluating the role of hemostatic factors on different types of strokes may help us identify new therapeutic strategies and different prognostic stratifications for ischemic stroke.
authors.affiliation: Department of Neurology and Internal Medicine, Dumlupinar University, School of Medicine, Kutahya, Turkey.
authors.forename: Demet
authors.initials: D
authors.lastname: Ilhan
authors.forename: Demet
authors.initials: D
authors.lastname: Ozbabalik
authors.forename: Erim
authors.initials: E
authors.lastname: Gulcan
authors.forename: Ozcan
authors.initials: O
authors.lastname: Ozdemir
authors.forename: Zafer
authors.initials: Z
authors.lastname: Gülbaçs
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000175:diagnosis; D020520:Brain Infarction / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology*; D002545:Brain Ischemia / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology*; D025901:Carboxypeptidase B2 / Q000032:analysis / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis / Q000378:metabolism; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000032:analysis / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000097:blood; D015539:Platelet Activation / Q000502:physiology; D010978:Platelet Factor 4 / Q000032:analysis / Q000097:blood; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D019007:P-Selectin; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C036309:fibrin fragment D; D010978:Platelet Factor 4; D025901:Carboxypeptidase B2